Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma : efficacy and tolerability in an elderly patient
The advent of immune checkpoint inhibitors anti-PD-1/PD-L1 has delivered new and effective treatment options with proven clinical benefits for patients affected by metastatic melanoma. The 30-40% of treated patients experience an objective tumour regression, with a significantly prolonged survival and an improved quality of life. Here, we report a case of a 75-year-old Caucasian woman affected by a massive cutaneous metastasis from a BRAF wild-type melanoma who experienced multiple relapses after surgery and repeated electrochemotherapy treatments. A poor response was observed after systemic therapy with ipilimumab, whereas a marked reduction in the lesion size was obtained during the treatment with nivolumab, with an objectively complete response after 6 months. Therapy was well tolerated, without immune-related side effects. During treatment, LDH levels decreased up to the standard values. Our experience confirms the good efficacy and the safety of anti-PD-1 nivolumab for the treatment of relapsed or refractory massive skin lesions, also in elderly patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Anti-cancer drugs - 28(2017), 7 vom: 24. Aug., Seite 808-810 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sponghini, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 04.12.2017 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/CAD.0000000000000515 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271747609 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271747609 | ||
| 003 | DE-627 | ||
| 005 | 20231224233402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CAD.0000000000000515 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0905.xml |
| 035 | |a (DE-627)NLM271747609 | ||
| 035 | |a (NLM)28489616 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sponghini, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma |b efficacy and tolerability in an elderly patient |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The advent of immune checkpoint inhibitors anti-PD-1/PD-L1 has delivered new and effective treatment options with proven clinical benefits for patients affected by metastatic melanoma. The 30-40% of treated patients experience an objective tumour regression, with a significantly prolonged survival and an improved quality of life. Here, we report a case of a 75-year-old Caucasian woman affected by a massive cutaneous metastasis from a BRAF wild-type melanoma who experienced multiple relapses after surgery and repeated electrochemotherapy treatments. A poor response was observed after systemic therapy with ipilimumab, whereas a marked reduction in the lesion size was obtained during the treatment with nivolumab, with an objectively complete response after 6 months. Therapy was well tolerated, without immune-related side effects. During treatment, LDH levels decreased up to the standard values. Our experience confirms the good efficacy and the safety of anti-PD-1 nivolumab for the treatment of relapsed or refractory massive skin lesions, also in elderly patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a PDCD1 protein, human |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 700 | 1 | |a Patrucco, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgione, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Farinelli, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Zottarelli, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Rondonotti, David |e verfasserin |4 aut | |
| 700 | 1 | |a Savoia, Paola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer drugs |d 1990 |g 28(2017), 7 vom: 24. Aug., Seite 808-810 |w (DE-627)NLM012606693 |x 1473-5741 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2017 |g number:7 |g day:24 |g month:08 |g pages:808-810 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CAD.0000000000000515 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2017 |e 7 |b 24 |c 08 |h 808-810 | ||